



Corporate Presentation

November 2021

Forward-Looking Statements

This presentation has been prepared by, and is the sole responsibility of, Hyloris Pharmaceuticals SA (the "Company") for discussions with investors in relation to the Company and its group. For the purposes of this notice, "presentation" means this document, oral presentation, any question and answer session and any written or oral material discussed or distributed during the presentation meetings. This presentation (or any part of it) may not be reproduced or redistributed, passed on, or the contents otherwise divulged, directly or indirectly, to any other person (whether inside or outside such person's organization or firm) or published for any purpose or under any circumstances.

This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any securities of the Company in any jurisdiction and neither it nor any part of it shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. This presentation does not contain all the information that a prospective purchaser of securities of the Company may desire or require in deciding whether or not to purchase such securities nor does it constitute a due diligence review and should not be construed as such. This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident in any jurisdiction where such distribution or use would be contrary to law or regulation or would require any registration or licensing within such jurisdiction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Any person into whose possession this presentation comes should inform themselves about, and observe, any such restrictions.

This presentation includes market, economic and industry data, which were obtained by the Company from scientific journals, industry publications, press releases, data published by government agencies, industry reports prepared by consultants and other market data providers. While the information has been accurately reproduced, and in as far as the Company is aware and is able to ascertain from such third-party information, no facts have been omitted which would render the reproduction of this third-party information inaccurate or misleading, the Company cannot guarantee its accuracy or completeness. Accordingly, you should not place reliance on any of the market, economic and industry data contained in this presentation.

This presentation includes statements that are, or may be deemed to be, "forward-looking statements" which are based on current expectations and projections about future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the words 'believe', 'estimate', 'anticipate', 'expect', 'intend', 'may', 'will', 'plan', 'continue', 'ongoing', 'possible', 'predict', 'plans', 'target', 'seek', 'would' or 'should', and contain statements made by the company regarding the intended results of its strategy. By their nature, these forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. A number of factors could cause actual results or outcomes to differ materially from those expressed, projected or implied in any forward-looking statements. In light of these risks, uncertainties and assumptions, the events or circumstances referred to in the forward-looking statements may not occur. None of the future projections, expectations, estimates or prospects in the materials should be taken as forecasts or promises nor should they be taken as implying any indication, assurance or guarantee that the assumptions on which such future projections, expectations, estimates or prospects have been prepared are correct or exhaustive or, in the case of the assumptions, fully stated in the materials. No one undertakes to publicly update or revise any such forward-looking statement, whether as a result of new information, future events or otherwise. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual results or otherwise.

By attending and otherwise accessing this presentation you will be deemed to have read and understood the contents of this disclaimer. In making an investment decision, you must rely on your own assessment, examination, analysis and enquiry of the Company.

Investment Highlights

Our Ambition

Creating value through rethinking and reinventing existing medications to become a leader in 505(b)(2) value-added medicines and address unmet medical needs

Our Values

Entrepreneurship, patient-centred care, commitment, mutual respect

Growth Pillars – Attractive Risk/Reward Profile

12 patented product candidates in the R&D pipeline

Spread across stages and indications

Expand with 4 candidate products on average per year

MULTIPLE SHOTS ON GOAL

2 products on the market with partners

Build our own lean commercial organisation in the U.S.

Addressing large areas of unmet medical needs

COMMERCIAL PORTFOLIO

Patients, partners, physicians and KOLs

Real-world data and payors' input

Outsourcing of non-core activities

VALUED PARTNERS

Executive Management Team

- In-depth knowledge of regulatory affairs, market access and the capital markets; involved in > 80 approved drugs, executed >250 licensing transactions; established track record of shareholder value creation
- Hyloris currently employs 23 people, 7 nationalities
- 50% of HYL shares owned by Van Rompay family and co-founder



Stijn Van Rompay - Chief Executive Officer

- >20 years of experience in leadership positions in pharma
- Co-founded, managed, and exited multiple pharma companies



Thomas Jacobsen - Chief Business Development Officer

- >20 years of experience in pharma
- Expertise in operational management, and business & product development



Dietmar Aichhorn - Chief Operating Officer

- >20 years of experience in various scientific roles in pharma
- Expert in technical and clinical development and regulatory affairs in the U.S., EU and other key geographies



Jean-Luc Vandebroek - Chief Financial Officer

- >25 years of executive financial leadership
- large, global network of investors and financial institutions



Koenraad Van der Elst - Chief Legal Officer

- >30 years of experience as external and in-house legal and general counsel at various listed companies
- Involved in numerous capital and M&A transactions worldwide



Our Strategy



Rethinking, Reinventing, Optimising Existing Medications

To improve overall therapy outcomes

REPURPOSING/
REPOSITIONING



New therapeutic uses


REFORMULATING



Changing dose and/or route of
administration


Strong health economics for patients, physicians, and payors

Patented Value-Added 505(b)(2) Products: Our Sweet Spot



Average Peak Sales of Value-Added 505(b)(2) Products

Average peak sales (million \$) of 505(b)(2) products in each approval year
2013 to 2018 (N=78 launched products)



Faster Innovation at Considerably Lower Costs and Risks




Putting Healthcare Needs at the Centre of Therapy Design


UNMET
MEDICAL
NEEDS




To Drive Continuous Growth and Create Shareholders' Value



Sourcing Product Opportunities Via Multiple Channels



Powerful R&D Engine: Leveraging our Network of Partners



Robust IP Portfolio: Extended Period of Exclusivity

















- Broad portfolio: exclusivity through 2039 in key pharma markets across the globe; orphan indications
- Wide range of protection: dosages, formulations, indications, methods for preparing a composition, manufacturing methods
- Additional layer of protection: knowhow, technological innovation and in-licensing

A close-up photograph of a hand wearing a blue nitrile medical glove. The gloved hand is gently holding the fingers of an older person's hand. The background is a soft-focus white surface, likely a hospital bedsheet. The overall tone is professional and caring.

Broad Product Portfolio to be Commercialised



Broad, Innovative Portfolio*: Expand to ~30 Assets by 2024

Product	Route of Administration	Indication	Formulation and Manufacturing	Clinical Development	Regulatory Filing	Target Market
CARDIOVASCULAR (CV) PORTFOLIO			Up to 7 years on average			
Sotalol IV	IV	Atrial fibrillation	Launched in U.S./partnered with AltaThera			
Aspirin IV U.S.	IV	Acute coronary syndrome				
Milrinone	Extended Release Capsule	Advanced heart failure (LVAD)				
Dofetilide IV	IV	Atrial fibrillation				
Metolazone IV	IV	Congestive heart failure				
HY-074	IV	Acute coronary syndrome				
HY-075	Oral Liquid	Coronary heart disease				
OTHER VALUE-ADDED PORTFOLIO			Up to 7 years on average			
Maxigesic® IV	IV	Post-operative pain	Licensed in >100 countries/partnered with AFT Pharmaceuticals			
TXA RTU	IV	Excessive bleeding				
HY-004	Oral Liquid	Specific dental indication				
Miconazole-DB	Topical	Severe and rVVC				
Plecoid™ Agent	IV	AML/SCLC				
Atomoxetine	Oral Liquid	ADHD				
HY-029	Oral Liquid	Viral infection				

* Our high barrier generic products, HY-038, HY-016 and Fusidic Acid Cream have not been included in the above overview

 Intended to be commercialised by Hyloris in the U.S.
 Intended to be commercialised with partner

Our Portfolio*: Added-Value for all Stakeholders

	Product	IP	Indication	Key Benefits, Value Proposition and Differentiating Features
CARDIOVASCULAR PORTFOLIO	Sotalol IV	'34-'38; granted	Atrial fibrillation	Shorter hospital stay; fast onset of action; lower overall healthcare cost; facilitate antiarrhythmic therapy for patients unable to swallow tablets
	Milrinone Oral	<i>Confidential</i>	Advanced heart failure	Extended release capsule with potential in LVAD patients who have developed right HF which could improve QoL and significantly reduce cost of care (lower readmission rates, faster discharge, at home administration for longer term use)
	Dofetilide IV	'39; pending	Atrial fibrillation	Shorter hospital stay; lower overall healthcare cost; facilitate antiarrhythmic therapy for patients unable to swallow tablets
	Metolazone IV	'38; pending	Congestive heart failure	Fast onset of action (essential in critical care) ; improved drug absorption and concomitant treatment possible
	Aspirin IV U.S.	'38, granted; pending	Acute Coronary Syndrome	Fast onset of action (essential in critical care) with low drug-drug interaction risk; prolonged, consistent effect; less intra- and interindividual metabolism variabilities; therapy possible in patients who are nauseous or unconscious
	HY-074	<i>Confidential</i>	Acute Coronary Syndrome	Fast onset of action (essential in critical care) with low drug-drug interaction risk; therapy possible in patients who are nauseous or unconscious
	HY-075	<i>Confidential</i>	Coronary heart disease	Possibility for drug titration, ease of administration and indicated dosage control
OTHER VALUE-ADDED PORTFOLIO	Maxigesic® IV	'30-'38; granted & pending	Pain	Highly effective non-opioid; tolerable profile; dual MOA; greater pain relief
	Miconazole-DB	'38; pending	sVVC/rVVC	Dual MOA; addressing population for whom there is currently no cure available
	HY-004	'39; granted & pending	Non-disclosed	Address acute issues or possible procedural related complications in dental offices
	Plecoid™ Agent	<i>Confidential</i>	AML/SCLC	Fixed dose combination of chelating agents to boost chemotherapy and detoxify the tumour micro-environment
	Atomoxetine	'36; granted	ADHD	Possibility for drug titration, ease of administration and indicated dosage control; improved compliance and convenience
	HY-029	<i>Confidential</i>	Viral infections	Possibility for drug titration; ease of administration and dosage control; improved compliance and clinical benefit
	Tranexamic Acid RTU	'39; granted	Excessive bleeding	Improved convenience and ease of use; potential as critical care product

Flexible, Hybrid Earnings and Commercialisation Model

CARDIOVASCULAR FRANCHISE

- Lean and efficient U.S. sales team targeting ~2,700 hospital-affiliated cardiologists
- Exploit existing regulatory package for certain product candidates to partner in other key geographies
- Already a presence in the U.S. with Sotalol IV, via commercial partner AltaThera

OTHER VALUE-ADDED PORTFOLIO

- Out-licensing to commercial partners across various geographies
- Create ability to quickly monetise assets via upfront and milestone payments
- Retain a large minority or small majority of net profit realised by partners



Financials, Outlook and Conclusion



Financial Highlights: Period Ending 30 June 2021

(in € thousand)	HY 2021	HY 2020	% change
Revenue and other income	1,145	102	1,023%
Revenues	838	82	922%
Other income	307	20	1,435%
Operating expenses	(9,016)	(3,626)	149%
R&D	(1,560)	(1,172)	33%
G&A	(1,608)	(2,454)	(34%)
Other (one-off expenses)	(5,770)	--	NA
Net cash (burn)/inflow ⁱ	(10,934)	66,578	NA
Cash and cash equivalents	53,465	66,783	(20%)

ⁱ For the period 1 January to 30 June

Key Factors
<ul style="list-style-type: none"> • Revenues: growth mainly driven by Maxigesic IV recognised income from milestones • Operating expenses: impacted by <u>one-off</u> expense related to unwinding of agreements with the Alter Pharma Group • Cash burn: <ul style="list-style-type: none"> ▪ HY21: impacted by one-off cash outflow related to unwinding of agreements with Alter Pharma Group ▪ HY20: positively impacted by financing activities (convertible bonds and IPO)

Achieved and Potential Near-Term Value Inflection Milestones

Clinical



HY-004: start Phase 1



MCZ-DB: start Phase 2 study in rVVC

- Atomoxetine: start pivotal study
- HY-004: Phase 1 safety results and preparations pivotal study
- Other assets: preparations to start pivotal studies

- Expand R&D pipeline with 1 additional product candidate

Regulatory



Tranexamic Acid RTU: marketing application in U.S.



Maxigesic IV: FDA acceptance of marketing application in U.S.



Maxigesic IV: additional approvals in key markets

Commercial



Partnership Purna Female Healthcare for MCZ-DB



Maxigesic IV: distribution agreements in EU and S. Am.; and U.S. (with Hikma)



Partnership with The Baker Institute for oral Milrinone



Maxigesic IV further roll-out



Partnership with Pleco for Plecoïd™ Agent in AML/SCLC

- Sotalol IV U.S. roll-out
- Commercial partnership(s)
- Out-licensing agreement(s)

Potential Game Changer, Geared for Growth

MULTIPLE SHOTS ON GOAL

12 Innovative, patented, value-added drug candidates

≤ 7 years to market

≤ €7 million average cost to market

Lower risk as we start from existing drugs

COMMERCIAL PORTFOLIO

2 patented products with partners

Addressing unmet needs

Build **U.S. commercial** team

Relevant improvements for patients, physicians and the healthcare system

Ambition to become the reference in value-added medicines over the coming years



investorrelations@hyloris.com



Addendum

- Selected case studies
- Background info 505(b)(2) pathway
- Corporate information



A photograph of a man with a shaved head and a goatee, wearing a blue t-shirt, carrying a young child with curly hair on his shoulders. They are in a lush green forest. The man is looking up and smiling, and the child is also smiling. The background is filled with tall trees and dense foliage.

Selected Case Studies


- Commercial products
- R&D pipeline



High Unmet Needs in Atrial Fibrillation (AF)

Atrial Fibrillation: a life-threatening disease

- Characterised by an irregular and often abnormal high heart rate



- Complications:** 5x higher risk of stroke², 3x higher risk of heart failure³
- Contributes to about **158,000 deaths** each year in the U.S.⁴
- U.S prevalence** expected to double to **12M by 2030**⁴
- 454,000**⁴ AF-related **hospitalisations** per year in the U.S.
- Majority** of hospitalised patients **receives** an **antiarrhythmic drug**


Current treatments could be improved

- Blood thinners
- Heart rate medicines
- Heart rhythm medicines**

LIMITATIONS

Rhythm control drugs have **life-threatening side effects**



FDA Oral sotalol carries black box warning



Incidence of *Torsade de Pointes* (abnormal heart rhythm – a serious side effect) is 0.5-5.8%⁵ on oral sotalol (dose-related)

Need for safer and more effective treatments

Sotalol IV Offers Benefits to Patients, Physicians and Payors



Approval Sotalol IV New Label (label extension)

NEW **SOTALOL IV™**
sotalol hydrochloride injection
10mL vial (15mg/mL)

New Dosing Information

American Heart Association

March 2020: FDA approval label extension to include the **initiation of loading** on Sotalol IV in patients who are prescribed oral sotalol and for **dose escalation** for chronic administration of an increased dose of oral sotalol


Commercialisation in the U.S. by Hyloris' partner

ALTATHERA PHARMACEUTICALS

Hyloris eligible to receive:

- Increasing sales-related fees on net sales derived from Sotalol IV in the U.S.
- Five one-time sales-related milestone payments of increasing amounts, totalling maximum \$18M
- First milestone to materialise when annual net sales are \geq \$20M


Sotalol IV New Label, Strong Support From Medical Community



Sotalol IV under its new label has potential to take an important share in the antiarrhythmic market

High Unmet Needs in Post-Operative Pain Management


Gap in moderately severe pain care space



Market size breakdown

Maxigesic® platform expected to generate **peak sales of \$442M** in U.S., Japan and EU5¹ (incl. Maxigesic® in oral form)²

Current treatment options are suboptimal



Hyloris entitled to a share on any revenues³ generated by commercial partner AFT




Maxigesic® IV has Potential to Combat the Opioid Crisis

Maxigesic® IV: a novel combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion, working in a complementary way to reduce both pain and inflammation and lower the use of opioid rescue medication




Faster onset & higher pain relief at each time point¹



- Double-blind, randomised, placebo-controlled Phase 3 study of Maxigesic IV in 276 patients following bunion surgery
- Onset of pain relief (VAS score) was significantly faster compared to placebo, paracetamol or ibuprofen alone and 30% less opioid consumption in the Maxigesic IV group
- At every time interval measurement, the VAS score was statistically better in the Maxigesic IV group



Opioid rescue medication: less used & used later²



- Double-blind, randomised, placebo-controlled Phase 3 of Maxigesic oral tablets in moderate to severe post-operative dental pain
- Mean total dose of rescue medication (oxycodone) in the Maxigesic oral group was significantly lower than in the other groups
- 87.2% of subjects in Maxigesic oral group achieved at least a 50% reduction in baseline VAS pain compared to the other groups without the use of rescue medication ($p < 0.05$)

Maxigesic IV: Significant Growth of Commercial Footprint




2021 year-to-date achievements:


- Launches in Germany and Austria
 - Expansion of license agreement in South America
 - License agreement with Hikma in the U.S.
- Europe: additional licenses and approvals
 - Patents granted across multiple jurisdictions
 - NDA submitted and accepted by the FDA

Toxic Metals in Tumour Micro-Environment Impact Survival

- Significant elevations of toxic metals have been detected in the bone marrow and blood of patients with Acute Myeloid Leukemia (AML) (*MD Anderson Cancer Center, Houston*)
- High levels of toxic metals are associated with inferior survival



Overall survival in AML patients with **high** and **low** serum cadmium levels




Overall survival in AML patients by groupings of metal scores

Many metals are implicated in disease progression: survival significantly worse in patients with higher metal scores

Plecoid™ Therapeutics: Partnership with Pleco

First-in-class combination products to boost chemotherapy:

- Based on breakthrough research at MD Anderson Cancer Center
- Designed to detoxify the cancer-promoting micro-environment
- Strong IP protection
- Opportunity in AML (~160K incident cases worldwide in 2018*) and Small Cell Lung Cancer (SCLC)



Scope

- HYL gains global exclusive co-development rights and future joined commercialisation
- To the Pleco technology in AML and SCLC

Financial terms


- HYL to provide €1M in several tranches over time – convertible into Pleco equity
- Subject to FDA feedback on the feasibility of clinical development requirements, Hyloris may commit up to an additional €7.7 million in pre-defined R&D activities through to submission for approval in AML + exploratory work in SCLC
- Pleco to fund all other activities outside the €7.7M provided by HYL
- HYL eligible to receive up to 65% of gross product margin in AML and SCLC

Responsibilities

- HYL responsible for CMC activities; co-responsible for licensing/commercial activities; co-responsible (and co-own) for IP
- Pleco responsible for product development and regulatory affairs; co-responsible for licensing/commercial activities; co-responsible (and co-own) for IP
- Joint steering and decision-making committee

Coronary Artery Disease and Acute Coronary Syndrome

Coronary Artery Disease




Normal heart and artery

Artery with plaque buildup

© University of Chicago
Medicine

Acute Coronary Syndrome (ACS)



~2 million patients/year in U.S.

- Acute myocardial infarction (heart attack)
- Unstable angina (chest pain)

#1 cause of death in the U.S.



Current SoC




Start ASAP treatment with oral Aspirin to stop platelet aggregation and avoid further damage to heart tissue: mortality risk is <26% in patients who receive SoC within 3 hours post ACS event

Potential Solution to Overcome Limitations of oral Aspirin

Oral Aspirin


- Slow onset of action: max. effect only after 1-2 hours
- Bioavailability of 40-50% and highly variable across patients: significant delayed effect or no effect
- Not suitable for patients who are unconscious/vomiting



Unpredictable onset of effect and risk of poor or delayed clinical response, which can be fatal

Aspirin IV: first-in-class IV acetylsalicylic acid

- Fast onset of action: avoid further heart tissue damage
- 100% bioavailability: immediate, consistent effect
- Higher inhibition of platelet aggregation
- Can be administered to all ACS patients



Major clinical benefits thanks to its fast, consistent anti-platelet effect, which is crucial in ACS

Aspirin IV in U.S.: start of pivotal study expected early 2022

Aspirin IV U.S.: Partnership with Rhoshan Pharmaceuticals

To address unmet needs in acute coronary syndrome (ACS):

- Can result in heart attack or unstable angina
- Higher risk of mortality 24 hours post heart attack
- Need for novel products with fast onset of action and consistent effect



Scope

- HYL to acquire worldwide rights to Rhoshan's novel, patented, breakthrough IV formulation technology
- Enables accelerated development of Aspirin IV in the U.S. (formerly known as HY-073, acetylsalicylic acid IV)

Financial terms

- HYL to provide maximum \$7.5M funding up to launch (\$750K at signing), of which 20% is reimbursable the first 3 years post launch
- Rhoshan eligible to receive up to \$1.25M development and regulatory milestones; plus commercial milestones and double-digit royalties


Responsibilities

- HYL responsible for manufacturing and commercialisation
- Rhoshan to continue product development and regulatory affairs activities


Heart Failure: #1 Cause of Hospitalisation in people >65 years

Heart failure (HF) occurs when the heart is unable to pump enough blood through the body

Causes and Risk Factors




Symptoms



2 Types


HFrEF (thin, weak heart muscle)

Heart failure with reduced ejection fraction



HFpEF (thick, stiff heart muscle)

Heart failure with preserved ejection fraction




By 2030, the annual HF-related cost in the U.S. is expected to be \$70 Bn



50% incurred in the hospital

HF Classification and Disease Management

As the condition gets worse, the heart muscle pumps less blood to the organs, and the patient moves toward the next stage of heart failure



IV Milrinone: Positive Inotrope = Increases Contractility


CARDIOPULMONARY EFFECTS:

- Increased contractility and heart rate
- Increased stroke volume and ejection fraction
- Increased cardiac output
- Decreased peripheral and pulmonary vascular resistance

- **Currently approved** for use as an intermittent or continuous infusion for treatment of up to 48 hours for acute decompensated heart failure
- **Longer term off-label** use exceeding 48 hours of treatment duration has been reported, requiring nursing support
- **Market:** >12 million vials and infusion bags sold in 2020, of which >2 million in the U.S. alone

Oral Milrinone: Our Potential Solution in LVAD RHF Patients

Epidemiology



~20,000 patients with an LVAD; 6% average annual growth rate expected over next years¹

30% will develop



right HF (RHF)

- Associated with very poor outcomes, including increased morbidity and mortality
- May require IV inotropic treatment

IV Milrinone: shortcomings

- Cumbersome, limiting patients' QoL
- High readmission rates post discharge
- High cost of care
- Not approved for long term use



Oral Milrinone Orphan Drug Status in U.S. in LVAD RHF

- Novel, orally administered extended-release capsule
- Positive results from earlier clinical studies: linear dose-response PK; well-tolerated and encouraging signs of effect in prolonged compassionate use phase*

This could potentially:

- Improve QoL
- Significantly reduce cost of care: lower readmission rates and faster discharge; administer at home by the patient for longer term use

Start of pivotal study in LVAD RHF patients expected end 2022/early 2023
Peak sales potential of \$50-\$80M in the U.S. in orphan LVAD right HF indication

Oral Milrinone: Partnership with The Baker Institute

To develop and commercialise a novel, patient-friendly oral formulation of Milrinone to meaningfully improve the lives of patients with advanced HF and significantly reduce cost of care



Scope

- HYL to acquire worldwide rights to CRD-102, a novel oral formulation of Milrinone in patients with advanced HF
- Potential to replace Milrinone IV and overcome current shortcomings to significantly improve the lives of patients with advanced HF and reduce cost of care

Financial terms

HYL to pay the Baker Institute:

- \$50K upfront signing fee
- In markets where HYL will self-commercialise: i) tiered single digit net profit share; ii) sales-based milestone payments
- In markets where HYL will seek commercial partnerships: tiered net profit share of net sub-license income

Responsibilities

- HYL responsible for product development, manufacturing, regulatory affairs and commercialisation
- The Baker Institute to provide R&D support

Unmet Needs in Severe and rVVC



Pain,
depression, shame,
isolation, fear

Current medicines have limitations



Local

Systemic

Vulvovaginal candidiasis (VVC)

- Infection caused by *Candida* sp. yeast
- Causes irritation, vaginal discharge and intense itchiness
- **Affects 50% of all women** during their life
- ~175 million drug products sold/year



Severe and recurring VVC

- **10% of all women globally**
- No effective treatments: drug-resistant biofilm
- \$14.4 Bn annual estimated economic burden

Treatment of acute VVC episodes - side effects

No innovation over the past few decades

Miconazole-DB has Potential to Cure Severe and rVVC




Domiphen Bromide (DB):

- Enables increased MCZ uptake in *Candida* cells at low doses
- Alters cytoplasmatic distribution of high azole doses
- Negatively affects vacuole integrity, thereby releasing vacuole-sequestered MCZ

Increased intracellular azole availability results in

- Increased ROS* generation = apoptosis
- Fungicidal antibiofilm activity

* ROS = reactive oxygen species



A person is running away from the camera on a wooden boardwalk that stretches into the distance. The scene is set at sunset, with a bright sun low on the horizon to the right, creating a strong lens flare and casting a warm, golden glow over the entire scene. The sky is filled with soft, wispy clouds. On either side of the boardwalk, there are lush green plants and some pink flowers in the foreground. The person running is wearing a light-colored long-sleeved shirt, light-colored leggings, and running shoes.

Market Landscape Value-Added 505(b)(2) Medicines



Performance of Select Number of 505(b)(2) Products

	Product name	What changed in 505(b)(2)	Indication	Company	2019 Sales
REFORMULATED	Avycaz	New combination	Complicated intra-abdominal and urinary tract infections	Allergan (AbbVie)	\$117M
	Belbuca	New dosage form	Chronic pain	BioDelivery Sciences	\$98M
	Vasostriect	New dosage form	Hypotension in adults with vasodilatory shock	Endo	\$531M
	Abraxane	New formulation	Metastatic breast cancer	Celgene (BMS)	\$1,200M
	Restasis	New route of administration	Chronic dry eye syndrome	Allergan (AbbVie)	\$1,188M
	Neoral	New formulation	Immunosuppressant to prevent organ rejection after kidney, heart or liver transplant	Sandoz (Novartis)	\$419M
	Kaletra	New combination and formulation	HIV infections	Abbott (AbbVie)	\$283M
REPURPOSED	Viagra	New indication	Erectile dysfunction	Pfizer	\$2,000M ^a
	Thalomid	New indication	Multiple myeloma	Celgene (BMS)	\$500M ^b
	Tecfidera	New indication	Multiple sclerosis	Biogen	\$4,430M
	Revatio	New indication	Pulmonary arterial hypertension	Pfizer	\$144M
	Propecia	New indication	Male pattern baldness	Merck	\$447M ^c
	Rituxan	New indication	Rheumatoid arthritis	Biogen & Roche	\$1,200M ^d

^a Sales in 2012, prior to generic entrants


^b Sales in 2008 prior introduction of Thalomid analogue drug Revlimid (Celgene)

^c Sales in 2010, prior to generic entrants


^d Sales in 2013, prior to biosimilar entrants

Increasing Use of 505(b)(2) Pathway in the Industry


505(b)(2) approvals (2003-2019)




NDA approvals in 2019 by pathway



505(b)(2) approvals by route of administration




505(b)(2) approvals by type



Value-Added 505(b)(2) Landscape

Geographical spread of 505(b)(2) (tentative) approvals 2015-2018 (# 221)













505(b)(2) (tentative) approvals 2015-2018

0 1 15 150

Top-3 applicants 2015-2018:

Country	Company	# of 505(b)(2) approvals
	 FRESENIUS KABI	12
	 SUN PHARMA	7
	 EXELA PHARMA SCIENCES	4

Select Listed Competitors:

Country	Company	# of 505(b)(2) approvals 2011 - 2019	Formulation route
	 EAGLE PHARMACEUTICALS	3	IV (infusion)
	 HERON THERAPEUTICS <small>Developing Better Oral Medicines Improving Lives</small>	2	Injection, injectable emulsion
	 eTon PHARMACEUTICALS	1	RTU injectable
	 PACIRA PHARMACEUTICALS, INC.	1	Injectable suspension
	 ani Pharmaceuticals, Inc.	Acquired a portfolio of 505(b)(2) product candidates from Coeptis	




Shareholders and Corporate Information



Shareholders' Information

Major shareholders



Bank	Analyst	Rating
KBC Securities	Jeroen Van den Bossche	Buy
Kempen	René Wouters	Buy
Berenberg	Beatrice Allen	Buy

Hyloris is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Hyloris' performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Hyloris or its management

HY21 cash position

€53.46 million

Share capital (excluding share premium)

€129,163.16

Total number of outstanding voting rights (= denominator)

25,832,632

Total number of securities carrying voting rights not yet issued

1,908,000

Hyloris Founders have an Impressive Industry Track Record

2005



Founded by Leon & Stijn Van Rompay
Generics and Pharmacy Sales & Devices

acquired for €218M

by



2013



Founded by Stijn Van Rompay & François Fornieri
Women's Health

acquired for up to \$305M

by



2015

Uteron shareholders

sold Estelle® for >€250M

to



2016

Novalon

Co-founded by Stijn Van Rompay
Controlled Release Implants

50% stake acquired for €9.4M

by



2017



Alter Pharma

Founded by Stijn Van Rompay & Thomas Jacobsen
Generics and Pharmacy Sales Products

partially acquired

by



Combined transactions created additional shareholder value of >€550 million

Board of Directors



Stefan Yee

Chairman, Non-Executive Director



Marc Foidart⁴

Independent Director



Stijn Van Rompay¹

Chief Executive Officer, Executive Director



Carolyn Myers

Independent Director



Thomas Jacobsen²

Chief Business Development Officer, Executive Director



James Gale

Independent Director



Leon Van Rompay³

Non-Executive Director



Chris Buyse⁵

Independent Director





investorrelations@hyloris.com

